在ITP少見的multi-center, randomized, double-blind, placebo-control trial
使用375mg/m2的rituximab連打四週
primary endpoint是詭異的78 week treatment failure rate
109個病患 Rituximab組有55人
78-week failure是 58% v.s 69%, p=.65
response rate: 81% v.s 73%, p=.15
唯一有差的是time to relapse: 36 v.s 7 weeks
原始文章
